Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification

Area of Science:

• Endocrinology
• Oncology
• Molecular Biology

Background:

• Parafibromin, a protein product of the hyperparathyroidism 2 (HRPT2) tumor suppressor gene, is linked to parathyroid cancer.
• Inactivation of HRPT2 is implicated in both familial and sporadic parathyroid malignancies.

Purpose of the Study:

• To evaluate the utility of parafibromin immunohistochemistry in classifying parathyroid tumors.
• To correlate parafibromin expression levels with tumor type and HRPT2 mutational status.

Main Methods:

• Immunohistochemistry was performed on 33 parathyroid carcinomas and 25 sporadic adenomas using four distinct parafibromin antibodies.
• HRPT2 mutational status was known for a subset of carcinoma cases.
• Western blot analysis was used to confirm parafibromin protein product size and localization.

Main Results:

• Reduced parafibromin expression was observed in 68% of unequivocal parathyroid carcinomas.
• All control sporadic adenomas showed positive parafibromin expression.
• Three of six carcinomas with known HRPT2 mutations exhibited reduced parafibromin expression.
• Comparable results were obtained across different parafibromin antibodies, indicating no specific epitope preference.

Conclusions:

• Parafibromin immunohistochemistry serves as a valuable adjunct marker for parathyroid tumor classification.
• Positive parafibromin expression suggests a low risk of malignancy.
• Reduced parafibromin expression may indicate parathyroid carcinoma or rare adenomas with HRPT2 mutations.